1. Endogenous Marinobufagenin-like Immunoreactive Factor and Na +,K + ATPase Inhibition During Voluntary Hypoventilation by Alexei Y. Bagrov, Olga V. Fedorova, Joy L. Austin-Lane, Renata I. Dmitrieva, and David E. Anderson Hypertension Volume 26(5):781-788 November 1, 1995 Copyright © American Heart Association, Inc. All rights reserved.

2. Left, single peak elution of ouabain (A), marinobufagenin (B), and digoxin (C) from Deltapak C18 reverse-phase columns (linear gradient of acetonitrile 10% to 80%, 0.1% trifluoroacetic acid). Alexei Y. Bagrov et al. Hypertension. 1995;26:781-788 Copyright © American Heart Association, Inc. All rights reserved.

3. Petco2 (A) and breathing frequency (B) at baseline (BL), during hypoventilation (HV), and after hypoventilation (recovery, RC). Alexei Y. Bagrov et al. Hypertension. 1995;26:781-788 Copyright © American Heart Association, Inc. All rights reserved.

4. Activity of Na+,K+-ATPase in nontreated erythrocytes (A) and erythrocytes treated with digoxin antibody (B) at baseline (BL), during hypoventilation (HV), and after hypoventilation (recovery, RC). Alexei Y. Bagrov et al. Hypertension. 1995;26:781-788 Copyright © American Heart Association, Inc. All rights reserved.

5. A, Plasma Na+,K+-ATPase inhibitory activity at baseline (BL), during hypoventilation (HV), and after hypoventilation (recovery, RC). *P<.05 vs BL. B, Relationship between erythrocyte Na+,K+- ATPase activity and plasma Na+,K+-ATPase inhibitory activity in 16 subjects during the experiment (BL, HV, and RC). r=.40, P<.02. Alexei Y. Bagrov et al. Hypertension. 1995;26:781-788 Copyright © American Heart Association, Inc. All rights reserved.

6. Plasma concentration of digitalis-like substances at baseline (BL), during hypoventilation (HV), and after hypoventilation (recovery, RC). Alexei Y. Bagrov et al. Hypertension. 1995;26:781-788 Copyright © American Heart Association, Inc. All rights reserved.

7. A and B, Elution profile of marinobufagenin-like immunoreactive substance from urinary extract on HPLC (Deltapak C18, isocratic elution with 32% acetonitrile and 0.1% trifluoroacetic acid, absorbance at 300 nm). Alexei Y. Bagrov et al. Hypertension. 1995;26:781-788 Copyright © American Heart Association, Inc. All rights reserved.